CHITA – a registry of in vitro NAMs
Check out the thoughtful and comprehensive review of AI in drug discovery by Andreas Bender and Isidro Cortés-Ciriano, Artificial intelligence in drug discovery: what is realistic, what are illusions? Part…
A recent paper from NTP showcases the application of mechanism-based NAMs for prediction of cardiotoxic potential. In a previous post, Getting Back on Track with NAMs at FDA, we encouraged…
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
